Camel Milk is an Alternative and a Complementary Treatment to the Current Parenteral Insulin Therapy of Insulin-dependent Diabetes Mellitus
The main treatment of insulin-dependent diabetes mellitus (IDDM) is insulin replacement via parenteral routes which is far from satisfactory, because injection is generally a painful procedure, especially when patients need to get the injections throughout their life by 2-3 injections/day. Secondly, many patients have phobia against injections especially children. Thirdly, insulin is expensive to purchase. Fourthly, parenteral insulin is not safe in the long-term of uses as development of anti-insulin antibodies is possible, and fifthly, parenteral insulin is associated with the risk of hypoglycemic events. For those reasons, raw dromedary’s camel milk is an alternative and or complementary to pareneral insulin treatment of IDDM. This paper discusses the chemical constituents and properties of dromedary’s camel milk, recent research about its efficacy in the treatment of IDDM, its role in the restoration of experimentally damaged beta-cells of the pancreas, its role in the improvement of lipid metabolism, body mass index and functions of the kidneys and liver of subjects with IDDM received camel milk. This paper demonstrates that, raw dromedary’s camel milk causes significant reduction in insulin doses in insulin dependent diabetic subjects to obtain glycemic control along with significant hypoglycemic effects. Significant improvement were also observed in HbA1c levels, micro albuminuria, lipid metabolism, BMI, biochemical parameters of the liver and kidney functions of camel milk fed experimental subjects with IDDM. Camel milk works as a regulator of blood sugar in the absence of original insulin, and it seems to work together with the body’s own restorative and regenerative abilities to maintain normal health. Camel milk is well tolerated and its uses are not associated with the risk of hypoglycemic events, and it may be able to eliminate the alloxan and other chemicals’ induced-toxicity on pancreas and on other body’s organs via regenerative effects on damaged cells with unknown mechanism and could be used as an alternative and or a complementary treatment to current IDDM therapy.
2. Sudan Federal Ministry of Health (2012). Press release. Alsahafa newspaper 09 November.
3. Sachdev B (2012). Screening of type 2 diabetes mellitus and its associated risk factors among select tribes of Rajasthan. IJHSR; V1 issue 1, 33-44.
4. Diabetes and retinopathy (Eye Complications) (2007). American Diabetes Association http://www.diabetes.org/diabetes-statistics/eye- complications. Jsp.
5. Li R, Wang ZG (2003). Analysis and forecast of the mortality of diabetes mellitus in China. J Environ Occupational Mod. 20:168-171.
6. Lee SH, Chun HK and Lee YS (2003). The effect of rice germ oil supplement on serum and hepatic lipid levels of streptozotocin-induced diabetic mice. Korean Journal of Nutrition; 36:543-5488.
7. Fujita H, Yamagami T and Ohshima K (2003). Long-term ingestion of Touchi extract, an α-glucosidase inhibitor, by borderline and mild type- 2 diabetic subjects is safe and significantly reduces blood glucose levels. Nutrition Research; 23:713–722.
8. Lee SH, Chun HK, Park HJ, Chang SO and Lee YS (2004). Effects of c-oryzanol on blood glucose in diabetic KK mice. Journal of the Korean Society of Food Science and Nutrition; 33:827- 831.
9. Lee SH, Park HJ, Cho SY, Han GJ, Chun HK and Hwang HG (2004). Supplementary effect of the high dietary fiber rice on lipid metabolism in diabetic KK mice. Korean Journal of Nutrition; 37:81-87.
10. Expert Committee on Diabetes Mellitus: Second Report (1980). Technical Report Series No. 646. World Health Organization; Geneva, 66 p.
11. Hu X, Sato J, Oshida Y, Yu M, Bajotto G, and Sato Y (2003). Effect of goshajinki-gan (Chinese herbal medicine: niu-che-sen-qi-wan) on insulin resistance in streptozotocin induced diabetic rats. Diabetes Research and Clinical Practice; 59:103-111.
12. Still JG (2002). Development of oral insulin: Progress and current status. Diabetes Metab. Res. Rev.; 18: S29-S37.
13. Chaillous L, Carel JC and Thivolet C, et al (1999). Lack of effect of one year oral insulin therapy in recent-onset type 1 diabetes: Results of a multicentric randomized controlled trial. Diabetologia; 42: A62- A62.
14. Kotb-El-Sayed M, Al-Shoeibi ZY, Ahmed A, Zayed AA (2011). Effects of camel’s milk as a vehicle for insulin on glycemic control and lipid profile in type 1 diabetes. American Journal of Biochemistry and Biotechnology; 7 (4): 179-189.
15. American Diabetes Association (2008). Diagnosis and classification of diabetes mellitus. Diabetes Care; 31:S55–S60.
16. Liu Sh, Zhang Y, Xie X, W Hu W, Cai R, and Huijun JK (2007). Application of two- dimensional electrophoresis in the research of retinal proteins of diabetic rat. J. of Cellular and molecular immunology; V 4: 65-70.
17. Dahlquist GG (1999). Primary and secondary prevention strategies of pre-type 1 diabetes: potentials and pitfall. Diabetes Care; 22 (Suppl. 2): B4-B6.
18. Sboui A, Djegham M, Khorchani T, Hammadi M, Barhoumi K, Belhadj O (2010). Effect of camel milk on blood glucose, cholesterol and total proteins variations in alloxan-induced diabetic dogs. Int’l J. of diabetes and metabolism; 18:5-11.
19. Yagil, R, Zagorski O, Creveld CV, and Saran A (1994). Science and Camel Milk Production. In: Chameaux et Dromedaires, Animeaux Laitiers, G. Saint-Martin, (Edn.); Expansion Scientifique Francaise, Paris, pp: 75-89.
20. Singh, R (2001). Annual Report of National Research Center on Camel. 1st Edn.; Bikaner, India, pp: 50.
21. Beg OU, Bahr-Lind HV; Zaidid ZH and Jhornvall H (1986b). Characterization of a camel milk protein rich in proline identifies a new beta-casein fragment. Regul. Pept., 15: 55-61.
22. Wangoh J (1993). What steps towards camel milk technology. Int. J. Anim. Sci., 8:9-11.
23. Shehadeh NL, Gelertner S, Blaxer R, Perlman Solovachik L, et al. (2001). Importance of insulin content in infant diet: Suggestion for a new infant formula. Acta. Paediatr., 90: 93-95.
24. Kamal O. Abdalla (2012). Treatment of Incurable Ailments with Camel's Milk and Urine, based on Scientific Research, book in Arabic (Elaaj Alamraad Almostasia Be-laban Wa-bool Al-ebeel, Be-esbaat Al-bahth Al-elmi). ISBN: 5-15-64-99942-978 . Int’l University of Africa Press. Sudan.
25. Davis SN, dobbins R, Colburn C, Tarumi C, Jacobs J, Neal D and Cherrington AD (1993). Effects of hyperinsulunemia in conscious dogs. American Journal of Physiology 264: E748-E755.
26. Wan CK, Giacca A, Matsuhisa M, Bahrani B, Lam L, Rodgers C and Shi ZO (2000). Increased reponse of glucagons and glucose production to hypeoglycemia with intraperitoneal verses subcutaneous insulin treatment. Metabolism 49: 984-989.
27. Pozzilli P, Pitocco D, Visalli N, . Cavallo MG, and Buzzetti R. et al. (2000). No effect of oral insulin on residual beta-cell function in recent-onset Type I diabetes (the IMDIAB VII). Diabetologia 43.
28. Agrawal RP, Sahani MS, Tuteja FC, Ghouri, SK, Sena DS, Gupta R, Kochar DK (2005). Hypoglycemic activity of camel milk in chemically pancreatectomized rats- An experimental study. Int J Diab Dev Countries 25: 75-79.
29. Yagil R, Saran A. and Etzion Z (1984). Camel's milk: for drinking only? Comp. Biochem. Physiol. A. 2: 263-266.
30. Agrawal RP, Kochar DK, Sahani MS, Tuteja FC, Ghorui SK (2004). Hypoglycemic activity of camel milk in streptozotocin induced diabetic rats. Int. J. Diab Dev Countries 24:47-49.
31. Yagil R (1987). Camel Milk. A Review. Int. J. Anim. Sci. 2: 81-89.
32. El-Agamy EI, Ruppanner R, Ismail A , Champagne CP, Assaf R (1992). Antibacterial and antiviral activity of camel milk protective proteins. J. Diary Res. 59: 169-175.
33. Yagil R, van Creveld C (2000). Medicinal use of camel milk. Fact or Fancy? In: Proc. 2nd Intl.Camelid Conf.Agro-economics of Camelid Farming. Almaty September P80.